sibeprenlimab (VIS649) / Otsuka  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sibeprenlimab (VIS649) / Otsuka
2019-002531-29: A study to look at the effect and how safe drug VIS649 is in patients with kidney disease

Not yet recruiting
2
144
Europe
VIS649, VIS649, Concentrate for solution for infusion
Visterra, Inc., Visterra, Inc.
Immunoglobulin A (IgA) Nephropathy, A kidney disease that occurs when antibody deposits build up in the kidneys, Diseases [C] - Immune System Diseases [C20]
 
 
ENVISION, NCT04287985: Safety and Efficacy Study of VIS649 for IgA Nephropathy

Completed
2
155
Europe, Canada, Japan, US, RoW
Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
Visterra, Inc.
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
05/23
06/23

Download Options